Search results
Showing results for
Researchers at the Kennedy Institute, part of NDORMS have repurposed the approved drug miglustat to successfully slow the progression of multiple myeloma.
Methods for the development and validation of computable phenotypes based on biobanks and linked real world data
Deadline - Friday 15 May 2026